NKGen Biotech, Inc. Warrants
NKGNW
NKGNW was delisted on the 4th of March, 2025.
30 hedge funds and large institutions have $346K invested in NKGen Biotech, Inc. Warrants in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 5 closing their positions.
74% more capital invested
Capital invested by funds: $198K → $346K (+$148K)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
3% less funds holding
Funds holding: 31 → 30 (-1)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$17K |
| 2 |
CAC
Cowen and Company
New York
|
+$2.83K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$2.24K |
| 4 |
VF
Virtu Financial
New York
|
+$1.55K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$568 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$9.93K |
| 2 |
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
|
-$6.46K |
| 3 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$4K |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$3.41K |
| 5 |
JFG
Jefferies Financial Group
New York
|
-$2.83K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCIA
26
Gabelli & Co Investment Advisers
Rye,
New York
| $2.76K | – | – | – |
|
|
GF
27
Gabelli Funds
Rye,
New York
| $2.75K | – | – | – |
|
|
CL
28
CSS LLC
Chicago,
Illinois
| $2.04K | – | – | – |
|
|
VF
29
Virtu Financial
New York
| $2K | +$1.55K | +13,631 | New |
|
30
UBS Group
Zurich,
Switzerland
| $1.64K | +$4 | +34 | +0.2% |
|
|
CCM
31
CAAS Capital Management
New York
| $1.6K | – | – | – |
|
|
AA
32
AQR Arbitrage
Greenwich,
Connecticut
| – | -$9.93K | -122,938 | Closed |
|
|
PSAMP
33
P. Schoenfeld Asset Management (PSAM)
New York
| – | -$6.46K | -80,000 | Closed |
|
|
JFG
34
Jefferies Financial Group
New York
| – | -$2.83K | -35,000 | Closed |
|
|
PI
35
PEAK6 Investments
Chicago,
Illinois
| – | -$892 | -11,039 | Closed |
|
|
CS
36
Clear Street
New York
| – | -$40 | -491 | Closed |
|
NKGNW Hedge Fund Activity: Q1 2024 in Review
30 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Warrants (NKGNW) for Q1 2024, worth a combined $346K — up 74% from $198K a quarter earlier.
Fund positioning in NKGNW was balanced in Q1 2024: 5 funds opened new positions, 5 closed out, 2 added to existing stakes and 5 trimmed.
The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $17K. The largest seller was AQR Arbitrage, exiting entirely with an estimated $9.93K sold.
- 30 institutional investors held NKGen Biotech, Inc. Warrants (NKGNW) as of Q1 2024, down from 31 in Q4 2023.
- Funds reported $346K of NKGen Biotech, Inc. Warrants stock for Q1 2024, up 74% quarter-over-quarter.
- 5 funds opened new NKGen Biotech, Inc. Warrants positions in Q1 2024 and 5 closed out, a net change of 0 holders.
- The largest NKGen Biotech, Inc. Warrants buyer in Q1 2024 was BNP Paribas Financial Markets, an estimated $17K added.
- The largest NKGen Biotech, Inc. Warrants seller in Q1 2024 was AQR Arbitrage, an estimated $9.93K sold.
Based on aggregated 13F filings for Q1 2024.